207 related articles for article (PubMed ID: 28550080)
21. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.
Chiang SS; Chen JB; Yang WC
Clin Nephrol; 2005 Jun; 63(6):461-70. PubMed ID: 15960148
[TBL] [Abstract][Full Text] [Related]
22. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
[TBL] [Abstract][Full Text] [Related]
23. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
24. MgCaCO3 versus CaCO3 in peritoneal dialysis patients--a cross-over pilot trial.
Evsanaa B; Liu I; Aliazardeh B; Mahdavi S; Bajwa G; Gula J; Tam M; Sze E; Roscoe JM; Tam PY; Sikaneta T
Perit Dial Int; 2015; 35(1):31-4. PubMed ID: 24584605
[TBL] [Abstract][Full Text] [Related]
25. Effect of lanthanum carbonate and calcium carbonate on the progression of coronary artery calcification among hemodialysis patients with vascular calcification risk: a randomized controlled trial.
Ogata H; Fukagawa M; Hirakata H; Kagimura T; Akizawa T;
Clin Exp Nephrol; 2022 Dec; 26(12):1223-1232. PubMed ID: 36064876
[TBL] [Abstract][Full Text] [Related]
26. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
Joy MS; Finn WF;
Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
[TBL] [Abstract][Full Text] [Related]
27. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S;
Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
[TBL] [Abstract][Full Text] [Related]
28. Design and Rationale of HiLo: A Pragmatic, Randomized Trial of Phosphate Management for Patients Receiving Maintenance Hemodialysis.
Edmonston DL; Isakova T; Dember LM; Brunelli S; Young A; Brosch R; Beddhu S; Chakraborty H; Wolf M
Am J Kidney Dis; 2021 Jun; 77(6):920-930.e1. PubMed ID: 33279558
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
[TBL] [Abstract][Full Text] [Related]
30. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
31. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden.
Hutchison AJ; Laville M;
Nephrol Dial Transplant; 2008 Nov; 23(11):3677-84. PubMed ID: 18577536
[TBL] [Abstract][Full Text] [Related]
32. Adherence to phosphate binders in hemodialysis patients: prevalence and determinants.
Van Camp YP; Vrijens B; Abraham I; Van Rompaey B; Elseviers MM
J Nephrol; 2014 Dec; 27(6):673-9. PubMed ID: 24563270
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.
Takahara Y; Matsuda Y; Takahashi S; Shigematsu T;
Clin Nephrol; 2014 Sep; 82(3):181-90. PubMed ID: 25079863
[TBL] [Abstract][Full Text] [Related]
34. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis.
Chen L; He JX; Chen YY; Ling YS; Lin CH; Guan TJ
Ren Fail; 2018 Nov; 40(1):15-21. PubMed ID: 29295646
[TBL] [Abstract][Full Text] [Related]
35. Phosphate Binders and Targets Over Decades: Do We have it Right Now?
Marcuccilli M; Chonchol M; Jovanovich A
Semin Dial; 2017 Mar; 30(2):134-141. PubMed ID: 28064444
[TBL] [Abstract][Full Text] [Related]
36. Management of phosphate abnormalities in hemodialysis patients: Findings from Malaysia.
Mohamed Koya SNM
Saudi J Kidney Dis Transpl; 2019; 30(3):670-677. PubMed ID: 31249232
[TBL] [Abstract][Full Text] [Related]
37. Feasibility study of colestipol as an oral phosphate binder in hemodialysis patients.
Hood CJ; Wolley MJ; Kam AL; Kendrik-Jones JC; Marshall MR
Nephrology (Carlton); 2015 Apr; 20(4):250-6. PubMed ID: 25557531
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
[TBL] [Abstract][Full Text] [Related]
39. Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis.
Bro S; Rasmussen RA; Handberg J; Olgaard K; Feldt-Rasmussen B
Am J Kidney Dis; 1998 Feb; 31(2):257-62. PubMed ID: 9469496
[TBL] [Abstract][Full Text] [Related]
40. The impact of accessibility to non-calcium-based phosphate binders and calcimimetics on mineral outcomes in patients receiving maintenance hemodialysis: A 10-year retrospective analysis of real-world data.
Disthabanchong S; Kasempin P; Srisuwarn P; Chansomboon P; Buachum N
PLoS One; 2024; 19(5):e0304649. PubMed ID: 38820324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
